key: cord-1043002-417u9w9f
authors: Liu, Jinbiao; Bodnar, Brittany H; Wang, Xu; Wang, Peng; Meng, Fengzhen; Khan, Adil I; Saribas, A Sami; Padhiar, Nigam H; McCluskey, Elizabeth; Shah, Sahil; Luo, Jin Jun; Hu, Wen-Hui; Ho, Wen-Zhe
title: Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants
date: 2021-05-31
journal: bioRxiv
DOI: 10.1101/2021.05.31.445871
sha: 0dcc6213017b3862bfe58dd9508a769591b2387d
doc_id: 1043002
cord_uid: 417u9w9f

Both Pfizer-BNT162b2 and Moderna-mRNA-1273 vaccines can elicit an effective immune response against SARS-CoV-2 infection. However, the elicited serum antibody levels vary substantially and longitudinally decrease after vaccination. We examined the correlation of vaccination-induced IgG levels and neutralization titers against newly emerged variants remains and demonstrate a significant reduction of neutralization activities against the variants (B.1.1.7, B.1.525, and B.1.351) in Pfizer or Moderna vaccined sera. There was a significant and positive correlation between serum IgG levels and ID50 titers for not only SARS-CoV-2 WT but also the variants. These findings indicate that a high level of anti-spike IgG may offer better protection against infection from SARS-CoV-2 and its variants. Therefore, it is necessary to longitudinally monitor specific serum IgG level for evaluating the protective efficacy of the vaccines against SARS-CoV-2 and its new variants.

The COVID-19 vaccines (Pfizer-BNT162b2 and Moderna-mRNA-1273) can elicit an effective immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 1, 2 . However, titers of elicited serum antibody and neutralizing activities against SARS-CoV-2 vary considerably among vaccinated individuals and decline after vaccination 3, 4 . Additionally, the protective efficacy of the vaccines against newly emerged variants remains to be elucidated. Therefore, it is of importance to understand the correlation between levels of vaccine-induced antibody and neutralizing activity against SARS-CoV-2, including the variants.

Methods: This study was approved by Temple University IRB (IRB #28021) and the informed consent forms were signed by all study subjects. Sera samples were obtained from 30 Pfizer vaccinated subjects (22-68 days after 2 nd dose) and 19 Moderna vaccinated subjects (24-49 days after 2 nd dose) (Supplemental content Table S1 ). Peripheral blood samples were collected three weeks to two months after the second dose of vaccine. The serum titers of specific IgG antibody to SARS-CoV-2 spike S1 by an enzyme-linked immunosorbent assay (ELISA). Table S2 ).

Serum neutralizing titers (50% inhibitory dilution, ID50) of all vaccinated subjects were determined using four-parameter logistic curve. Geometric mean titers (GMTs) were calculated with 95% CI. Wilcoxon matched-pairs signed rank test was used for two-group analysis. Pearson's correlation coefficients were calculated. P values less than 0.05 were statistically significant. groups. This finding is consistent with and supported by recent reports 5, 6 . Despite an overall decline in neutralizing titers (GMTs) against the variants, sera at low dilution (1:50) could neutralize 99% of both SARS-CoV-2 WT pseudovirus and the variants (D614G, B.1.1.7, B.1.525, and B.1.351) (Supplementary Appendix   Fig. S2 and S3) 

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Immunogenicity of Two RNA-Based Covid-19

Vaccine Candidates

Durability of Responses after SARS-CoV-2 mRNA-1273

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination